

Case Blog

Title: Sclerosing Basal Cell Carcinoma

Alex H Wong¹, Alexander KC Leung^{2*} and Benjamin Barankin³

¹Department of Family Medicine, University of Calgary, Canada

²Department of Pediatrics, University of Calgary; Pediatric Consultant, Alberta Children's Hospital, Canada

³Toronto Dermatology Centre, Canada



An 85-year-old Caucasian man presented with a slowly growing, asymptomatic, linear, scar-like lesion just above the right clavicle for almost four years. There was no history of weight loss or regional lymphadenopathy. He participated in many outdoor activities such as swimming when he was young. A punch biopsy of the lesion showed nests of basaloid cells arranged in elongated strands and embedded in a dense fibrous stroma, extending down from the epidermis into the deeper dermis. These features were consistent with a sclerosing basal cell carcinoma.

Basal cell carcinoma (BCC) is generally defined as a locally invasive, slowly spreading tumor that rarely metastasizes, arising in the epidermis or hair follicles. The exact incidence is not known. In the UK, there were approximately 200,000 patients with BCCs treated surgically in 2010. This number does not include those treated by other means. The incidence increases with age, with a peak during the sixth to eight decades. The male to female ratio is approximately 1.5 to 2:1. The greatest risk factor is chronic exposure to ultraviolet radiation as evidenced by a higher frequency of disease in sun-exposed areas. Other risk factors include fair skin color, history of blistering sunburns (particularly in childhood), freckles in childhood, ionizing radiation, indoor tanning exposure, arsenic exposure, immunosuppression, close relatives with skin cancers, and mutations in tumour suppressor genes such as *p53* and patched homologue 1 (*PTCH 1*).

BCCs are a heterogeneous group of tumors that based on their clinical morphology can be classified most commonly into the following subtypes: nodular BCC, superficial BCC, sclerosing BCC, infiltrative BCC, micronodular BCC, and pigmented BCC. Sclerosing BCC accounts for approximately 0.6% of all BCCs. It affects mainly the face as a depressed plaque or scar with ill-defined borders. In fact, a sclerosing BCC is also called “cicatricial” or “morpheic” BCC for that reason. The tumor is locally invasive and tends to extend into the dermis beyond the level where it is clinically visible or palpable. It can have an extensive subclinical spread, making complete excision difficult. Although sclerosing BCC rarely metastasizes, it carries a higher risk of local recurrence; periodic lifelong monitoring is advised to detect recurrence as well as to identify other skin cancers and pre-cancers (i.e., actinic keratoses).

*Corresponding author: Alexander KC Leung, MBBS, FRCPC, FRCP (UK and Ireland), FRCPCH, FAAP, Clinical Professor of Pediatrics, the University of Calgary, #200, 233 – 16th Avenue NW Calgary, Alberta, T2M 0H5, Canada, Telefax: (403) 230-3322; E-mail: aleung@ucalgary.ca

Copyright: © 2015 Wong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.